Our results showed that RBBP4 protein expression levels were significantly downregulated in a contraction-related manner in the ropivacaine-treated group compared to the control group (Fig. 4A), indicating that ropivacaine reduced RBBP4 expression in lung cancer cells. The gene discussed is RBBP4; the disease is lung carcinoma.